Trials
3 active
4 in total · 2 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Genetically modified herpes simplex type 1 virus for tumor lysis and immune stimulation.”In the company’s words, NCT06581406 on ClinicalTrials.gov
- Main trialPhase 2/3
- “The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been treated with immune checkpoint inhibitor therapy.”In the company’s words, NCT06581406 on ClinicalTrials.gov
Other drugs for Metastatic Uveal Melanoma
- DarovasertibIDEAYA Biosciences · Phase 3
- AU-011Aura Biosciences · Phase 3
- Melphalan/HDSDelcath Systems Inc. · Phase 3
- EB-DTKN-401Beijing Biotech · Phase 1/2
- DYP688Novartis Pharmaceuticals · Phase 1/2
- RoginolisibiOnctura · Phase 2
Coming up2
- 1 Dec 2027Phase 2 trial completes · ClinicalTrials.gov
- Jan 2030Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Recruiting | Jan 2030 | A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma | |
| Phase 2Recruiting | 1 Dec 2027 | Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC | |
| Phase 1Active, not recruiting | 31 Oct 2026 | Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors | |
| Phase 2Terminated | 18 Aug 2025 | RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026